MetaCap

BioNTech SE ADR Company Profile

NASDAQ: BNTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

80.96-0.42 (-0.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BioNTech at a glance

BioNTech SE ADR (NASDAQ: BNTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Mainz, Germany. BioNTech is led by Dr. Ugur Sahin M.D. and employs about 7,807 people. The company's shares have traded publicly since 2019.

At a market capitalization of $20.44 billion, it is considered a large-cap company. Its SEC Central Index Key (CIK) is 0001776985, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does BioNTech do?

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Business description based on the company's public filings.

Company information

Legal name
BioNTech SE ADR
Ticker
NASDAQ: BNTX
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Ugur Sahin M.D.
Employees
7,807
Headquarters
An der Goldgrube 12, Mainz, Germany
Phone
49 6131 9084
IPO year
2019
Market cap
$20.44B
SEC CIK
0001776985

Companies similar to BioNTech

BNTX peer companies
CompanyPrice% ChgMarket capCompare
EXELExelixis Inc.64.63-1.82%$15.77Bvs BNTX
NBIXNeurocrine Biosciences Inc.150.57-3.84%$15.24Bvs BNTX
TECHBio-Techne Corp72.67-0.04%$11.42Bvs BNTX
RGENRepligen Corporation163.81-3.81%$10.47Bvs BNTX
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs BNTX
QGENQiagen N.V.49.30-0.66%$10.18Bvs BNTX
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs BNTX
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs BNTX

Related